Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella typhimurium

Human Gene Therapy

Volumn 18, Issue 8, 2007, Pages 746-752

  Xie, Can ^a   He, Jin Sheng ^a,b   Zhang, Mei ^a   Xue, Shao Li ^a   Wu, Qiang ^a   Ding, Xiang Dong ^a   Song, Wei ^a   Yuan, Yuan ^a   Li, Dong Liang ^a   Zheng, Xian Xian ^a   Lu, Yan Yan ^a   Shang, Zhi ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BEIJING JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PLASMID DNA; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS F PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; FEMALE; HISTOPATHOLOGY; LOWER RESPIRATORY TRACT INFECTION; LUNG LAVAGE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; SALMONELLA TYPHIMURIUM; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; SALMONELLA TYPHIMURIUM; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL PROTEINS;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SALMONELLA; SALMONELLA TYPHIMURIUM;

EID: 34548490545     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.053     Document Type: Article

References (23)

1. ANDERSON, L.J., HIERHOLZER, J.C., TSOU, C., HENDRY, R.M., FERNIE, B.F., STONE, Y., and MCINTOSH, K. (1985). Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J. Infect. Dis. 151, 626-633.
2. BRANDENBURG, A.H., NEIJENS, H.J., and OSTERHAUS, A.D. (2001). Pathogenesis of RSV lower respiratory tract infection: Implications for vaccine development. Vaccine 19, 2769-2782.
3. CHERRIE, A.H., ANDERSON, K., WERTZ, G.W., and OPENSHAW, J.W. (1992). Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J. Virol. 66, 2102-2110.
4. th edit. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, and S.E. Straus, eds. (Lippincott Williams & Wilkins, Philadelphia) pp. 1601-1646.
5. CONNORS, M., COLLINS, P.L., FIRESTONE, C.Y., and MURPHY, B.R. (1991). Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65, 1634-1637.
6. DARJI, A., GUZMÁN, C.A., GERSTEL, B., WACHHOLZ, P., TIMMIS, K.N., WEHLAND, J., CHAKRABORTY, T., and WEISS, S. (1997). Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765-775.
7. DAUDEL, D., WEIDINGER, G., and SPRENG, S. (2007). Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev. Vaccines 6, 97-110.
8. DUNSTAN, S.J., SIMMONS, C.P., and STRUGNELL, R.A. (1998). Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen. Infect. Immun. 66, 732-740.
9. FERNIE, B.F., FORD, E.C., and GERIN, J.L. (1981). The development of BALB/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface. Proc. Soc. Exp. Biol. Med. 167, 83-86.
10. GARCIA-BARRENO, B., JORCANO, J.L., AUKENBAUER, T., LÓPEZ- GALÍNDEZ, C., and MELERO, J.A. (1988). Participation of cytoskeletal intermediate filaments in the infectious cycle of human respiratory syncytial virus (RSV). Virus Res. 9, 307-321.
11. GRAHAM, B.S., BUNTON, L.A., WRIGHT, P.F., and KARZON, D.T. (1991). Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88, 1026-1033.
12. GUY, B., PASCAL, N., FRANCON, A., BONNIN, A., GIMENEZ, S., LAFAY-VIALON, E., TRANNOY, E., and HAENSLER, J. (2001). Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 19, 1794-1805.
13. HALL, C.B. (2001). Respiratory syncytial virus and parainfluenza virus. N. Engl. J. Med. 344, 1917-1928.
14. JOHNSON, P.R., and COLLINS, P.L. (1988). The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: Sequence conservation provides a structural basis for antigenic relatedness. J. Gen. Virol. 69, 2623-2628.
15. KARRON, R.A. (2004). Respiratory syncytial virus vaccine. In Plotkin, S.A., and Orenstein, W.A., eds. Vaccines, 4 ed. (W.B. Saunders, Philadelphia, PA) pp. 1317-1326.
16. KIM, H.W., CANCHOLA, J.G., BRANDT, C.D., PYLES, G., CHANOCK, R.M., JENSEN, K., and PARROTT, R.H. (1969). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J. Epidemiol. 89, 422-434.
17. KUMAR, M., BEHERA, A.K., LOCKEY, R.F., ZHANG, J., BHULLAR, G., DE LA CRUZ, C.P., CHEN, L.C., LEONG, K.W., HUANG, S.K., and MOHAPATRA, S.S. (2002). Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum. Gene Ther. 13, 1415-25.
18. LI, X., SAMBHARA, S., LI, C.X., ETTORRE, L., SWITZER, I., CATES, G., JAMES, O., PARRINGTON, M., OOMEN, R., DU, R.P., and KLEIN, M. (2000). Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 269, 54-65.
19. MICHAEL, A., STRATFORD, R., KHAN, S., DALGLEISH, A., and PANDHA, H. (2004). Novel strains of Salmonella typhimurium as potential vectors for gene delivery. FEMS Microbiol. Lett. 238, 345-351.
20. NICHOLAS, J.A., RUBINO, K.L., LEVELY, M.E., ADAMS, E.G., and COLLINS, P.L. (1990). Cytolytic T-lymphocyte responses to respiratory syncytial virus: Effector cell phenotype and target proteins. J. Virol. 64, 4232-4241.
21. OPENSHAW, P.J., CULLEY, F.J., and OLSZEWSKA, W. (2001). Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20(Suppl. 1), S27-S31.
22. ROY, K., MAO, H.Q., HUANG, S.K., and LEONG, K.W. (1999). Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5, 387-391.
23. SIRARD, J.C., NIEDERGANG, F., and KRAEHENBUHL, J.P. (1999). Live attenuated Salmonella: A paradigm of mucosal vaccines. Immunol. Rev. 171, 5-26.